Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions – September 17

Live Nationwide CME Webcast!
Thursday, September 17, 2020
8:00 PM – 9:00 PM (ET)
7:00 PM – 8:00 PM (CT)
6:00 PM – 7:00 PM (MT)
5:00 PM – 6:00 PM (PT)

 

Join us for this
LIVE Nationwide Interactive CME Webcast!

 

PROGRAM OVERVIEW

Until recently, treatment options for severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome were limited mostly to immunosuppression with oral corticosteroids (OCS) or other systemic agents. An expanding understanding of the pathophysiology of these diseases has led to the identification of newer therapeutic targets and more selective and better tolerated treatments for eosinophil reduction. This interactive webcast will review strategies for recognizing these phenotypes of severe eosinophilic diseases of the lungs and help the clinician better navigate available treatments in order to improve symptoms, lighten the disease burden, and reduce exacerbations and OCS reliance for patients with severe asthma and associated eosinophil-mediated conditions.

PRACTITIONER’S EDGESM FORMAT

This dynamic Practitioner’s EdgeSM webcast will utilize the collective results of an interactive case study simulation completed by participants prior to the program. Upon registration, instructions for the case study simulation will be provided. Faculty members will compile and review the participants’ responses to the simulation during the live webcast, which will serve as a catalyst for discussion and best-practice reinforcement. Interactive polling questions and a 3D animation will also be available during the live program to review treatment of severe asthma and associated eosinophil-mediated conditions.

 

FACULTY PRESENTER

Monica Kraft, MD
Robert & Irene Flinn Endowed Professor of Medicine
Chair, Department of Medicine
University of Arizona
Tucson, Arizona

 

TARGET AUDIENCE

This educational initiative is intended for allergists, pulmonologists, nurse practitioners, physician assistants, and other practitioners who manage patients with asthma and associated eosinophil-mediated conditions.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why rarer orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma
  • Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on OCS

ACCREDITATION

Physician Continuing Education

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must complete the preprogram case study simulation, the pretest and posttest, view the live Webcast, and complete the evaluation form. A statement of credit will be issued only upon submission of a completed activity evaluation form.

FEE INFORMATION

There is no fee for this educational activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosures
Monica Kraft, MD
Research: ALA, AstraZeneca, Chiesi, NIH, Sanofi (funds paid to institution)
Royalty: Elsevier
Consultant: AstraZeneca, Sanofi

Integrity Continuing Education planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from GlaxoSmithKline.

Agenda

Please use link below to access the live webcast on the day of the event.
https://integrityce.com/severeasthma

Please go through the case and diagnose and treat our patient with severe asthma just as you would in your own practice. Your response is required no later than September 7, 2020. Our experts will provide feedback to your approach (anonymized) as part of their discussion on September 17.